High-dose Wegovy debuts at $399 for self-paying patients
Paige Twenter / beckershospitalreview - Novo Nordisk’s recently approved high-dose Wegovy formulation has entered the U.S. market and is available for $399 per month for self-paying patients, the drugmaker said April 7. In March, the FDA approved Wegovy HD, a 7.2-mg injection of semaglutide, as…
AI Summary: Novo Nordisk has introduced a higher‑dose formulation of Wegovy (semaglutide) in the U.S., offering self‑pay patients access at a $399 monthly price. The rollout reflects growing demand for GLP‑1 therapies and fuels ongoing debates about affordability, access and how much of weight‑management care should depend on out‑of‑pocket spending.
- On scene: industry shifts, IPOs, stigma and miscellaneous reports (4)
- On site: Novo rolls out Wegovy HD, sparking access debates (7)
- Regulators press for more GLP-1 safety data and oversight (4)
- Reporting from clinics: GLP-1s vary in effect, risk muscle loss (9)
- All Other Stories
On scene: industry shifts, IPOs, stigma and miscellaneous reports
On site: Novo rolls out Wegovy HD, sparking access debates
Regulators press for more GLP-1 safety data and oversight
Reporting from clinics: GLP-1s vary in effect, risk muscle loss
All Other Stories
AbbVie sues HHS over 340B patient definition
Ella Jeffries / beckershospitalreview - AbbVie has filed a lawsuit challenging federal guidance on how “patient” is defined under the 340B program, according to an April 8 press release. The company said the current definition, based on guidance issued in 1996, allows covered entities to claim …
AI Summary: AbbVie has filed suit challenging HHS’s interpretation of the 340B program, arguing the agency’s “patient” definition and related guidance are outdated and legally flawed. The company seeks judicial clarity that could reshape who qualifies for discounted drugs and how hospitals and manufacturers navigate the program — yes, the pricing drama continues.
Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggest
Elizabeth Cairns / endpoints - Eli Lilly’s so-called triple-G reduced blood sugar levels in patients with type 2 diabetes by up to 1.9% in a late-stage trial — a similar margin as Mounjaro achieved in its pivotal diabetes study. The triple-G ...
AI Summary: Eli Lilly’s third‑generation GLP‑1 candidate reported Phase 3 data demonstrating significant weight loss and A1C reductions, with efficacy appearing comparable to existing therapies like Mounjaro. The results sharpen competition in the GLP‑1 market and raise questions about pricing, access and who gets first dibs on the next blockbuster injection.
- At clinics: GLP‑1 demand reshaping access, care and pricing (5)
- In labs: oral pills and novel GLP‑1 delivery approaches (4)
- On the ground: Lilly's triple‑G rivaling Mounjaro in trials (3)
- Other: clinical oddities, surgical implications and pipeline setbacks (5)
At clinics: GLP‑1 demand reshaping access, care and pricing
In labs: oral pills and novel GLP‑1 delivery approaches
On the ground: Lilly's triple‑G rivaling Mounjaro in trials
Other: clinical oddities, surgical implications and pipeline setbacks
Gallup poll: One in three Americans cutting back on daily expenses to pay for healthcare
fiercehealthcare - Healthcare affordability remains a significant challenge, with a third of respondents to a new Gallup poll saying they had to cut back on daily living expenses to afford care.
AI Summary: A Gallup poll reports one-third of Americans trimmed everyday spending, borrowed money or skipped essentials to pay medical bills. The findings highlight acute affordability pressures that force families to choose between care and basic needs, underscoring systemic gaps in coverage and cost control while policymakers offer the usual sympathetic nod.
Eli Lilly's new program aims to boost employer coverage of GLP-1s
Shelby Livingston / endpoints - With insurance coverage of weight loss medications stalled, Eli Lilly has developed a program to give employers another way to pay for their workers' GLP-1 treatments. The pharma giant on Thursday announced the launch of ...
AI Summary: Eli Lilly unveiled an Employer Connect program designed to help employers expand coverage for GLP‑1–class weight‑loss drugs amid stalled insurer uptake. The initiative offers new contracting and access pathways for workplaces, addressing demand while prompting debate over whether it changes the underlying benefit‑design economics. It’s helpful—if you don’t expect a revolution.
Optum Rx, Caremark making ‘significant progress’ in settlement talks with FTC
Rebecca Pifer Parduhn / healthcaredive - It’s looking increasingly likely that the UnitedHealth and CVS drug middlemen will also make peace with federal regulators, after Cigna agreed to a sweeping settlement in the insulin lawsuit last month.
AI Summary: Federal regulators and two pharmacy benefit managers are reportedly making substantial progress toward resolving an FTC antitrust probe tied to insulin pricing and PBM practices. Negotiations aim to settle allegations without protracted litigation, potentially changing how PBMs operate and how insulin costs are managed for states and patients.
Hospitals urge regulators to halt drugmakers’ expanded 340B data policies
Emily Olsen / healthcaredive - The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful.
AI Summary: Hospitals and provider groups are urging federal regulators to halt new drugmaker policies that expand claims-data reporting tied to 340B discounts, calling the requirements unlawful and administratively burdensome. The dispute pits safety-net providers against manufacturers seeking program transparency — a classic tug-of-war with patients’ financial stakes caught in the middle.
AbbVie sues over selection of Botox for IRA negotiations
Nicole DeFeudis / endpoints - AbbVie is suing CMS for picking Botox for the third round of Medicare negotiations, making it the first drugmaker to challenge the upcoming cycle in court. In a lawsuit filed Wednesday in Washington, DC, AbbVie ...
AI Summary: AbbVie has filed suit challenging the federal decision to include Botox in Medicare’s drug price negotiation program, arguing the selection process was flawed and that the move could imperil innovation and pricing strategies. The lawsuit seeks to block or alter implementation while the industry and regulators brace for legal precedent.
HHS to drop 340B rebate pilot after court rulings
Ella Jeffries / beckershospitalreview - HHS will drop its 340B rebate model pilot program following two federal court rulings that blocked its implementation. The program, announced in August 2025, was challenged by the American Hospital Association, the Maine Hospital Association and four safe…
AI Summary: In a twist that no one saw coming (except the federal courts), HHS has scrapped its controversial 340B rebate pilot after two judicial rulings blocked its implementation. Providers, relieved to avoid a potential cash flow nightmare, are quietly celebrating the decision as one less bureaucratic headache to manage.
HHS scraps 340B rebate pilot in win for hospitals
Emily Olsen / healthcaredive - The Trump administration agreed to drop a controversial pilot that would have allowed drugmakers to give post-sales rebates on some drugs instead of upfront discounts.
AI Summary: Federal health officials have reversed course on a highly controversial 340B rebate pilot program after federal courts blocked its implementation – a move hailed by providers as a long‐awaited relief from cash flow and administrative burdens.
Novo Nordisk vows legal action to protect Wegovy pill
medicalxpress - Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.
AI Summary: Novo Nordisk has vowed to take legal action after discovering that competitors – including Hims & Hers – plan to market a compounded, lower‐priced version of its new Wegovy weight‐loss pill. The company is mobilizing its legal team to protect its intellectual property amid fierce market competition.
FTC deal over insulin prices forces Express Scripts to overhaul policies
Elizabeth Casolo / beckershospitalreview - The Federal Trade Commission reached a settlement with Cigna’s Express Scripts in a case over alleged inflation of insulin prices, according to a Feb. 4 agency news release. Under the settlement, Express Scripts must keep drug manufacturer compensation de…
AI Summary: Federal regulators reached a settlement with Express Scripts amid long‐standing allegations that the pharmacy benefit manager overcharged for insulin. The deal forces sweeping policy revisions to curb price inflation and protect patients from rising costs, following years of regulatory scrutiny over insulin rebate practices.
‘Vertical integration is destroying people’s ability to access care’: Payer CEOs face bipartisan congressional grilling
Jakob Emerson / beckershospitalreview - The CEOs of the nation’s largest health insurers drew the ire of lawmakers on both sides of the aisle during congressional hearings Jan. 22 over industry consolidation, prior authorization practices and executive pay, with members pressing executives to e…
AI Summary: Lawmakers grilled top health insurance executives in a high‐profile congressional hearing over rising healthcare costs, vertical integration and shifting of cost burdens to hospitals and drug makers. The grilling highlighted deep concerns over patient access and systemic inefficiencies in American healthcare.
Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access
Ella Jeffries / beckershospitalreview - Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 medications and suppress competition. The lawsuit, filed i…
AI Summary: A compounding pharmacy has taken legal aim at industry giants Eli Lilly and Novo Nordisk, alleging an anti‑competitive scheme designed to restrict access to their blockbuster GLP‑1 therapies. The lawsuit puts the pharmaceutical titans on the defensive as antitrust concerns mix with therapeutic access debates.
Judge blocks 340B rebate pilot program
Ella Jeffries / beckershospitalreview - A federal judge granted a temporary restraining order blocking the Department of Health and Human Services from launching its 340B Rebate Model Pilot Program, which was scheduled to begin Jan. 1, 2026. U.S. District Judge Lance Walker of the District of M…
AI Summary: A federal judge has temporarily halted the rollout of a 340B rebate pilot program designed to reshape drug pricing ahead of its January start. The ruling challenges the current administration’s approach to reforming pricing models, casting uncertainty on the initiative’s future.
House floats new healthcare bill after Senate proposals fail
Andrew Cass / beckershospitalreview - House Republicans have unveiled new healthcare legislation in the wake of votes in the Senate that failed to pass bills addressing expiring ACA enhanced subsidies. Seven things to know: 1. The House Republicans’ proposal does not extend the subsidies that…
AI Summary: House Republicans have introduced new legislation aimed at containing rising healthcare costs after recent Senate proposals failed. Notably, the bill deliberately excludes any extension of ACA subsidies or changes to health savings accounts, signaling a distinctly partisan approach that is already stirring debate on its future impact.
Optum Rx: 100% of network community pharmacies shift to cost-based model
fiercehealthcare - Earlier this year, Optum Rx announced that it would shift to a cost-based model, which would boost reimbursements for brand-name drugs at community pharmacies.
AI Summary: In a significant payment model overhaul, Optum Rx has moved 100% of its community and independent pharmacies to a cost‐based model, a change aimed at aligning reimbursements with actual expenses and enhancing pharmacy viability in a challenging market.
ACA approval hits new high as subsidies set to expire: 7 things to know
Alan Condon / beckershospitalreview - Approval of the ACA recently climbed to a new high of 57% — driven largely by a surge in support among independents — even as pandemic‑era enhanced subsidies are set to expire Dec. 31 unless Congress acts, according to a survey published Dec. 8 by the Wes…
AI Summary: Multiple reports point to growing concerns that the impending expiration of expanded Affordable Care Act subsidies could leave millions facing steep premium hikes or loss of coverage. Survey findings and policy analyses underscore the potential financial strain on vulnerable populations as the deadline nears.
CVS Health agrees to pay $37.8M to settle fraud allegations over insulin pens
fiercehealthcare - CVS Health agreed to pay $37.76 million to settle allegations that it dispensed too many insulin pens to patients and improperly billed federal healthcare programs for those prescriptions.
AI Summary: CVS Health has agreed to pay approximately $38 million to settle allegations that it improperly dispensed insulin pens and misbilled federal health programs, resolving accusations of fraudulent practices and restoring trust in its operations.
UK and US agree zero-tariff deal on pharmaceuticals
go - Officials say the U.K. has sealed a deal securing a 0% tariff rate for all U.K. medicines exported to the U.S. for at least 3 years, in return for the U.K. spending more on new medicines
AI Summary: In a twist worthy of a Hollywood trade drama, officials announced that the UK and US have struck a deal to impose zero tariffs on UK‐made medicines destined for the US. As part of the arrangement, the UK must shell out considerably more for drug pricing—a move set to avoid tariffs that could soar as high as 100%—with the agreement effective for at least three years.